Donate

Octapharma USA Announces FDA Approval of NUWIQ New Product Strengths

August 23, 2017

Note: The following is an edited version of a press release from Octapharma USA.聽Read the press release from Octapharma USA聽in it鈥檚 entirety here. Octapharma USA today announced the U.S. Food and Drug Administration (FDA) has approved new product strengths for NUWIQ. The agency approved new single dose NUWIQ聽vial strengths of 2500, 3000 and 4000 International […]

Octapharma Presents Phase III NuProtect Data at 2016 ASH Annual Meeting

December 22, 2016

______________________________________________________________________________ Note: The following is edited from a聽press release from Octapharma. Read the full press release in it鈥檚 entirety聽here. At the recent American Society of Hematology (ASH) Annual Meeting, Octapharma presented interim data from the ongoing phase 3 study,聽NuProtect. The NuProtect Study examines the immunogenicity, efficacy and safety of treatment with human cell-line derived recombinant […]

Octapharma Announces US Availability of NUWIQ

January 4, 2016

聽Note: The following is an edited press release from Octapharma USA. The original release can be read in its entirety聽here. Octapharma USA announced on Monday, January 4, 2016 that NUWIQ庐, Antihemophilic Factor (Recombinant), is now commercially available. NUWIQ庐 is indicated for the treatment and control of bleeding, perioperative (surgical) management, and routine prophylaxis to reduce […]

FDA Approves New Octapharma Treatment For Patients With Hemophilia A

September 15, 2015

Note: This is an edited form of a press release from Octapharma. To read the original release in its entirety,聽click here. Octapharma USA announced on September 15, 2015, that the U.S. Food and Drug Administration (FDA) has approved NUWIQ庐, Antihemophilic Factor (Recombinant), an intravenous therapy for adults and children living with Hemophilia A. The NUWIQ庐 […]

Octapharma鈥檚 Hemophilia A Product Approved in Europe

August 7, 2014

The European Commission has published approval of Octapharma鈥檚 Nuwiq 庐 (simoctocog alfa) for the treatment and prophylaxis of bleeding in all age groups with hemophilia A (congenital factor VIII [FVIII] deficiency). Nuwiq 庐 is the newest generation of FVIII replacement, produced in a human cell line cultured without additives of human or animal origin. Nuwiq […]


Sign up for E-mails, Dateline Magazine, and other ways to stay connected.